Spyre Therapeutics’ monoclonal antibody hit the key goal of a phase 2 study in ulcerative colitis, which the company has touted as proof it can best Takeda’s Entyvio.
- Home |
- Spyre points to phase 2 win for ulcerative colitis drug as proof it could take on Takeda’s Entyvio
Spyre points to phase 2 win for ulcerative colitis drug as proof it could take on Takeda’s Entyvio
- April 13, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
